Summary of a workshop on potency and dosage of von Willebrand factor concentrates
- 1 November 1998
- journal article
- Published by Wiley in Haemophilia
- Vol. 4 (S3), 1-6
- https://doi.org/10.1046/j.1365-2516.1998.0040s3001.x
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Pharmacokinetics, efficacy and safety of Humate‐P® in von Willebrand diseaseHaemophilia, 1998
- In vitro evaluation of the haemostatic value of the LFB-von Willebrand factor concentrateHaemophilia, 1998
- Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2Haemophilia, 1998
- Clinical management of patients with von Willebrand’s disease with a VHP vWF concentrate: the French experienceHaemophilia, 1998
- Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand diseaseHaemophilia, 1998
- Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysisHaemophilia, 1998
- Identification of aspartic acid 514 through glutamic acid 542 as a glycoprotein Ib-IX complex receptor recognition sequence in von Willebrand factor. Mechanism of modulation of von Willebrand factor by ristocetin and botrocetinBiochemistry, 1992
- The effect of von Willebrand factor on activation of factor VIII by factor XaEuropean Journal of Biochemistry, 1990
- Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor.Journal of Clinical Investigation, 1988
- Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Willebrand's diseaseJournal of Clinical Investigation, 1971